Department of Breast Surgery, Research Unit of General Surgery, the First Affiliated Hospital of China Medical University, and Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences of China Medical University, Shenyang, Liaoning Province, (110001), China.
J Exp Clin Cancer Res. 2010 Aug 16;29(1):112. doi: 10.1186/1756-9966-29-112.
Women with ductal hyperplasia including usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH) have an increased risk of developing invasive ductal carcinoma (IDC) of breast. The importance of several molecular markers in breast cancer has been of considerable interest during recent years such as p53 and estrogen receptor alpha (ERalpha). However, p53 nuclear accumulation and ERalpha expression have not been assessed in ductal hyperplasia co-existing with ductal carcinoma in situ (DCIS) or IDC versus pure ductal hyperplasia without DCIS or IDC.
We investigated p53 nuclear accumulation and ERalpha expression in breast ductal hyperplasia in a cohort of 215 Chinese women by immunohistochemistry (IHC), which included 129 cases of pure ductal hyperplasia, 86 cases of ductal hyperplasia co-existing with DCIS (41 cases) or IDC (45 cases).
Nuclear p53 accumulation was identified in 22.8% of ADH (31/136), 41.5% of DCIS (17/41) and 42.2% of IDC (19/45), and no case of UDH (0/79). No difference in nuclear p53 accumulation was observed between pure ADH and ADH co-existing with DCIS (ADH/DCIS) or IDC (ADH/IDC) (P>0.05). The positive rate of ERalpha expression was lower in ADH (118/136, 86.8%) than that in UDH (79/79, 100%) (P<0.001), but higher than that in DCIS (28/41, 68.3%) or IDC (26/45, 57.8%) respectively (P<0.001). The frequency of ERalpha expression was lower in ADH/DCIS (23/29, 79.31%) and ADH/IDC (23/30, 76.67%) than that in pure ADH (72/77, 93.51%) respectively (P<0.05). There was a negative weak correlation between p53 nuclear accumulation and ERalpha expression as for ADH (coefficient correlation -0.51; P<0.001).
Different pathological types of ductal hyperplasia of breast are accompanied by diversity in patterns of nuclear p53 accumulation and ERalpha expression. At least some pure ADH is molecularly distinct from ADH/CIS or ADH/IDC which indicated the two types of ADH are molecularly distinct entities although they have the same morphological appearance.
患有导管增生（包括普通型导管增生和非典型性导管增生）的女性患乳腺癌的风险增加。近年来，p53 和雌激素受体 alpha（ERalpha）等几种分子标志物在乳腺癌中的重要性引起了相当大的关注。然而，p53 核积累和 ERalpha 表达在导管增生伴导管原位癌（DCIS）或浸润性导管癌（IDC）与无 DCIS 或 IDC 的单纯导管增生中的评估尚未进行。
我们通过免疫组织化学（IHC）检测了 215 例中国女性的乳腺导管增生中的 p53 核积累和 ERalpha 表达，其中包括 129 例单纯导管增生、86 例导管增生伴 DCIS（41 例）或 IDC（45 例）。
ADH（31/136）中核 p53 积累的发生率为 22.8%，DCIS（17/41）为 41.5%，IDC（19/45）为 42.2%，而 UDH（0/79）中没有病例。单纯 ADH 与 ADH 伴 DCIS（ADH/DCIS）或 IDC（ADH/IDC）之间核 p53 积累无差异（P>0.05）。ADH（118/136，86.8%）的 ERalpha 表达阳性率低于 UDH（79/79，100%）（P<0.001），但高于 DCIS（28/41，68.3%）或 IDC（26/45，57.8%）（P<0.001）。ADH/DCIS（23/29，79.31%）和 ADH/IDC（23/30，76.67%）的 ERalpha 表达频率均低于单纯 ADH（72/77，93.51%）（P<0.05）。ADH 中 p53 核积累和 ERalpha 表达呈负弱相关（相关系数-0.51；P<0.001）。
不同类型的乳腺导管增生伴有核 p53 积累和 ERalpha 表达模式的多样性。至少一些单纯的 ADH 在分子上与 ADH/CIS 或 ADH/IDC 不同，这表明这两种类型的 ADH 虽然具有相同的形态学表现，但在分子上是不同的实体。
Zotero 插件
